[HTML][HTML] COVID‐19 patients exhibit reduced procoagulant platelet responses

F Denorme, BK Manne, I Portier, AC Petrey… - Journal of Thrombosis …, 2020 - Elsevier
Background Emerging evidence implicates dysfunctional platelet responses in thrombotic
complications in COVID‐19 patients. Platelets are important players in inflammation …

[HTML][HTML] Inflammation drives coagulopathies in SARS-CoV-2 Patients

MMS Sim, M Banerjee, M Hollifield, H Alfar, X Li… - Blood, 2020 - Elsevier
Background: A hypercoagulable state has been consistently reported in patients with severe
Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome …

[HTML][HTML] Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation

C Wang, C Yu, H Jing, X Wu, VA Novakovic… - Frontiers in Cellular …, 2022 - frontiersin.org
Many discharged COVID-19 patients affected by sequelae experience reduced quality of life
leading to an increased burden on the healthcare system, their families and society at large …

Extracellular vesicles released in blood of COVID-19 patients: mechanism for detection of cardiac troponin after myocardial injury?

AHB Wu, Y Zhang, R Webber - Biomarkers, 2020 - Taylor & Francis
The 2019 coronavirus pandemic has led to the deaths of hundreds of thousands of
individuals worldwide. The most frequent causes include complications of sepsis, acute …

Acute to post-acute COVID-19 thromboinflammation persistence: Mechanisms and potential consequences

RM Gonçalves, ED Hottz, PT Bozza - 2023 - arca.fiocruz.br
Concerns for the long-term effects of COVID-19 infection have grown due to frequently
reported persisting symptoms that can affect multiple systems for longer than 4 weeks after …

SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk …

C Bao, X Tao, W Cui, B Yi, T Pan, KH Young… - … Hematology & Oncology, 2020 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19) is a novel infectious viral
disease, which lacks well-established diagnostic laboratory parameters that could be used …

Monocyte-Mediated Thrombosis Linked to Circulating Tissue Factor and Immune Paralysis in COVID-19

SN Goonewardena, Q Chen, AM Tate… - … and Vascular Biology, 2024 - Am Heart Assoc
BACKGROUND: SARS-CoV-2 infections cause COVID-19 and are associated with
inflammation, coagulopathy, and high incidence of thrombosis. Myeloid cells help …

Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) …

TJ Girard, L Antunes, N Zhang, JM Amrute… - Journal of Thrombosis …, 2023 - Elsevier
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
associated with excessive coagulation, thrombosis, and mortality. Objective To provide …

[HTML][HTML] Heparin induced thrombocytopenia in patients with COVID-19

S Warrior, E Behrens, S Gezer, P Venugopal, S Jain - Blood, 2020 - Elsevier
Background The Coronavirus disease-2019 (COVID-19) is a global pandemic caused by
novel coronavirus SARS-CoV-2. Acute respiratory and renal failure as well as systemic …

Procoagulant activity of extracellular vesicles in plasma of patients with SARS-CoV-2 infection

L Theresa - EBioMedicine, 2021 - thelancet.com
Extracellular vesicles (EVs) have been of special interest in recent years. Emerging
evidence suggests that EVs play a key role in health and disease [1]. Released by all cell …